← Back to Search

Beta Blocker

Beta Blocker vs Calcium Channel Blocker for Stable Angina (LIVEBETTER Trial)

Phase 4

Recruiting

Led By Michael Nanna, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 75 years

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 6 months and 12 months

Awards & highlights

LIVEBETTER Trial Summary

This trial evaluates how well anti-anginal drugs work & are tolerated in older adults w/ SIHD & multiple chronic conditions.

Who is the study for?

This trial is for older adults aged 75 and above with stable angina, heart disease, and at least two other chronic conditions. They must be planning to start medical therapy for their heart condition but can't have severe reactions to beta-blockers or calcium channel blockers, nor plans for immediate complete revascularization.Check my eligibility

What is being tested?

The study tests the effectiveness of standard anti-anginal medications (beta-blockers and calcium channel blockers) in managing symptoms of Stable Ischemic Heart Disease in seniors with multiple health issues. The choice of medication is left to the clinician's discretion.See study design

What are the potential side effects?

Potential side effects from beta-blockers may include fatigue, cold hands or feet, weight gain, depression or sleep problems. Calcium channel blockers might cause headaches, swelling in the lower legs and feet, dizziness or constipation.

LIVEBETTER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 75 years old or older.

Select...

I am 18 years old or older.

Select...

I have two or more long-term health conditions.

Select...

I have heart disease with significant artery blockage and plan to start treatment.

LIVEBETTER Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 6 months and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 6 months and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 months and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Change in 6-minute walk test

Change in Angina Control assessed using Seattle Angina Questionnaire (SAQ) Summary Score

Change in Caregiver Burden Inventory

+3 more

LIVEBETTER Trial Design

2Treatment groups

Experimental Treatment

Group I: Calcium Channel Blockers (CCB) TherapyExperimental Treatment2 Interventions

Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).

Group II: Beta-Blockers (BB) TherapyExperimental Treatment2 Interventions

Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Beta blocker

2015

Completed Phase 4

~420

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor

1,852 Previous Clinical Trials

2,737,481 Total Patients Enrolled

2 Trials studying Ischemic Heart Disease

41 Patients Enrolled for Ischemic Heart Disease

Michael Nanna, MDPrincipal InvestigatorYale University

Media Library

Beta blocker (Beta Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05786417 — Phase 4

Ischemic Heart Disease Research Study Groups: Calcium Channel Blockers (CCB) Therapy, Beta-Blockers (BB) Therapy

Ischemic Heart Disease Clinical Trial 2023: Beta blocker Highlights & Side Effects. Trial Name: NCT05786417 — Phase 4

Beta blocker (Beta Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05786417 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the FDA sanction Beta-Blockers Therapy?

"There is ample evidence suggesting the safety of Beta-Blockers (BB) Therapy, so it has been awarded a score of 3. This Phase 4 trial confirms that BB Therapy is approved for medical use."

Answered by AI

Is this experiment amenable to applicants at the present time?

"As clinicaltrials.gov reveals, this trial is no longer accepting participants. It was initially posted on April 1st 2023 and has not been amended since March 23rd 2023. Fortunately, 815 other trials are still actively recruiting patients at the present moment."

Answered by AI

How many locales are hosting this experiment?

"This clinical trial is recruiting participants from Yale School of Medicine (New Haven, Connecticut), Brigham and Women's Hospital (Boston, Massachusetts) Duke University - School of Medicine (Durham, North carolina) in addition to 5 other sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

2023. "LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05786417.